Physician profile
Steven M Shumer
NPI 1346231214
$2,457.01
in general payments reported to CMS, 2019-2025
32 companies · $327 in 2025
The $327 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $204 · 2021: $190 · 2022: $480 · 2023: $230 · 2024: $449 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.69 | 2019-2025 | Skyrizi |
| Sun Pharmaceutical Industries INC. | $224.99 | 2021-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $218.82 | 2019-2024 | |
| Lilly USA, LLC | $209.96 | 2019-2024 | Olumiant, Taltz |
| Janssen Biotech, INC. | $184.22 | 2019-2025 | Tremfya |
| Promius Pharma LLC | $124.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $120.25 | 2019-2022 | |
| Amgen INC. | $105.55 | 2022-2023 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.42 | 2019-2024 | Jublia, Cabtreo |
| Pfizer INC. | $81.25 | 2020-2022 | |
| Genzyme Corporation | $71.14 | 2019-2020 | |
| Ucb, INC. | $70.67 | 2019-2024 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.04 | 2023-2025 | Spevigo |
| Kerecis Limited | $54.22 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Leo Pharma INC. | $39.10 | 2022-2024 | Adbry |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $37.04 | 2019-2025 | Aklief |
| Almirall LLC | $35.18 | 2020-2021 | |
| Verrica Pharmaceuticals INC. | $32.17 | 2023-2024 | Ycanth |
| Organon LLC | $29.46 | 2025 | |
| Biofrontera INC. | $28.77 | 2019-2020 | |
| Strata Skin Sciences, INC. | $28.67 | 2025 | Xtrac |
| Mallinckrodt Hospital Products INC. | $28.46 | 2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $25.30 | 2023 | Sotyktu |
| Dermavant Sciences, INC. | $19.57 | 2024 | Vtama |
| Allergan, INC. | $19.11 | 2022 | |
| Nabriva Therapeutics, Plc | $19.03 | 2021 | |
| Sandoz INC. | $18.73 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.18 | 2019 | |
| Kyowa Kirin, INC. | $15.65 | 2025 | |
| Aclaris Therapeutics, INC. | $14.60 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.27 | 2019 | |
| Melinta Therapeutics, LLC | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shumer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.